Acne Medication Market Scope And Analysis

Report Code : TIPRE00004587
Category : Life Sciences

Status : Published
No. of Pages : 229

Buy Now

Acne Medication Market Analysis, Scope, and Growth by 2030

Buy Now

Acne Medication Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 7.77 Billion
Market Size by 2030	US$ 11.8 Billion
Global CAGR (2022 - 2030)	5.40%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Therapeutic Class Retinoids Benzoyl Peroxide Antibiotics Salicylic Acid By Formulation Topical Medication and Oral Medication By Type Prescription Medicine and Over-the-Counter Medicine By Acne Type Non-Inflammatory Acne and Inflammatory Acne
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Teva Pharmaceutical Industries Ltd Mayne Pharma Group Ltd Almirall SA Johnson Johnson Sun Pharmaceutical Industries Ltd Bausch Health Companies Inc Centro Internacional de Cosmiatria SA de CV Galderma SA Pfizer Inc GSK Plc Viatris Inc

Industry Developments and Future Opportunities:

Different initiatives by prominent players in the global acne medication market, as per company press releases, are listed below:

In September 2023, Cosmo Pharmaceuticals NV (Ireland) and Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals (Mumbai), announced signing distribution and licensing arrangements for the distribution of Winlevi (1% clascoterone cream) in South Africa and Europe. The agreements state that Glenmark will get sole rights to market Winlevi in 15 EU nations (Sapin, Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, and Sweden), as well as in South Africa and the UK, via Cassiopea, a Cosmo subsidiary.
In October 2023, Crown Therapeutics, a branch of Crown Laboratories, added two new PanOxyl products—PanOxyl Clarifying Exfoliant with 2% salicylic acid and PanOxyl Adapalene 0.1% gel—to its dermatologist-endorsed and award-winning PanOxyl range. In September 2023, Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, announced the accessibility of WINLEVI (clascoterone cream, 1% w/w) in Canada. For patients 12 years of age and older, WINLEVI is the first and only androgen receptor inhibitor recommended for the topical treatment of acne vulgaris, or acne.

Competitive Landscape and Key Companies:

Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Sun Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc., GSK Plc, Viatris Inc, Somar Sapi De CV, Carnot Technologies, and Italmex SA are a few key companies profiled in the acne medication market report. These companies focus on the development and adoption of new technologies, advancements in existing products, and expansion of their geographic presence to meet the growing consumer demand worldwide.